Enterovirus 71 vaccine: close but still far.
BACKGROUND
Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field.


METHODS
Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed.


RESULTS
Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development.


CONCLUSIONS
The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.
Zhang
Dingmei
D
School of Public Health, Sun Yat-sen University, Laboratory for Tropical Disease Control and Prevention, Guangdong Provincial Research Center for Severe Infectious Disease Prevention and Control Technology, Guangzhou 510080, China.
Lu
Jiayuan
J
Lu
Jiahai
J
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D029821:Enterovirus A, Human / Q000276:immunology*; D004769:Enterovirus Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D000939:Epitopes / Q000276:immunology; D006232:Hand, Foot and Mouth Disease / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D000939:Epitopes; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
Vaccine. 2002 Jun 7;20(19-20):2485-93
12057603
Vaccine. 2004 Sep 28;22(29-30):3858-64
15364432
Acta Virol. 2005;49(1):17-22
15929394
Vaccine. 2008 Jun 2;26(23):2882-9
18450335
Vaccine. 2006 Apr 5;24(15):2944-51
16448730
Pediatrics. 2007 Aug;120(2):e244-52
17671037
J Virol. 2008 Feb;82(4):1787-97
18057246
Microbes Infect. 2007 Sep;9(11):1299-306
17890123
Expert Rev Vaccines. 2009 Jan;8(1):35-41
19093771
Proc Natl Acad Sci U S A. 1987 Jun;84(12):4002-6
3035560
Arch Virol. 1982;71(3):217-27
6285858
Genet Vaccines Ther. 2003 Sep 16;1(1):2
14606963
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10527-31
1438241
Biochem Biophys Res Commun. 2009 Dec 25;390(4):1126-8
19799860
Eur J Pediatr. 2008 Nov;167(11):1335-8
18317803
Vaccine. 2007 Jan 2;25(1):19-24
16919374
Arch Dis Child. 1980 Aug;55(8):583-8
6254449
J Infect Dis. 1974 Mar;129(3):304-9
4361245
Annu Rev Immunol. 2000;18:927-74
10837079
Virus Res. 2007 Apr;125(1):61-8
17222936
Jpn J Med Sci Biol. 1981 Jun;34(3):191-6
6273621
Clin Microbiol Rev. 1992 Jul;5(3):328-42
1498769
J Biotechnol. 2003 Apr 24;102(2):105-15
12697387
Vaccine. 2007 Nov 1;25(44):7664-73
17913305
J Clin Microbiol. 2002 Aug;40(8):2823-7
12149336
Pediatrics. 2002 Jun;109(6):e88
12042582
J Virol. 2007 Sep;81(17):9386-95
17567701
Microbes Infect. 2006 Jun;8(7):1671-8
16815726
N Engl J Med. 1999 Sep 23;341(13):929-35
10498487
Vaccine. 2001 Aug 14;19(31):4429-33
11483268
J Paediatr Child Health. 2000 Aug;36(4):408-11
10940185
Int J Pharm. 2008 Feb 12;349(1-2):226-33
17825506
Annu Rev Microbiol. 2005;59:587-635
16153180
Genet Vaccines Ther. 2007 Apr 19;5:6
17445254
Biotechnol Lett. 2003 Jun;25(12):919-25
12889824
Biochem Biophys Res Commun. 2004 Jun 11;318(4):833-8
15147946
J Microbiol Immunol Infect. 2000 Dec;33(4):205-16
11269363
J Biomed Sci. 2000 Nov-Dec;7(6):523-8
11060501
J Clin Microbiol. 2009 Jul;47(7):2351-2
19439545
Pediatr Infect Dis J. 1987 Feb;6(2):206-8
3562141
Viral Immunol. 2008 Jun;21(2):215-24
18419256
J Gen Virol. 2005 May;86(Pt 5):1391-1401
15831951
Wkly Epidemiol Rec. 2008 May 9;83(19):169-70
18472450
Vaccine. 2003 May 1;21(16):1769-75
12686092
Vaccine. 2007 May 10;25(19):3731-41
17350735
Vaccine. 2001 Dec 12;20(5-6):895-904
11738755
Lancet. 1974 Jul 13;2(7872):112
4136956
Expert Rev Vaccines. 2009 Jan;8(1):5-8
19093765
Pediatr Infect Dis J. 1988 Jul;7(7):484-8
2841639
Microbiol Immunol. 2002;46(9):621-7
12437029
Expert Rev Vaccines. 2008 Aug;7(6):729-38
18665772
Vaccine. 2008 Mar 28;26(15):1855-62
18329759
World J Gastroenterol. 2006 Feb 14;12(6):921-7
16521221